SCO-267

• Description :

  SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1].

• UNSPSC :

  12352005

• Target :

  Free Fatty Acid Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/sco-267.html

• Purity :

  99.88

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C)(C)CN(C1=CC=CC(C)=N1)C(C2=C(N3CCC(CC3)COC4=CC([C@H](C5CC5)CC(O)=O)=CC=N4)C=C(C=C2)OC)=O

• Molecular Formula :

  C36H46N4O5

• Molecular Weight :

  614.77

• References & Citations :

  [1]Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99 (4) :286-293.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1656261-09-4]